<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Rev Paul Pediatr</journal-id>
<journal-id journal-id-type="iso-abbrev">Rev Paul Pediatr</journal-id>
<journal-id journal-id-type="publisher-id">rpp</journal-id>
<journal-title-group>
<journal-title>Revista Paulista de Pediatria</journal-title>
</journal-title-group>
<issn pub-type="ppub">0103-0582</issn>
<issn pub-type="epub">1984-0462</issn>
<publisher>
<publisher-name>Sociedade de Pediatria de São Paulo</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32520295</article-id>
<article-id pub-id-type="pmc">7274528</article-id>
<article-id pub-id-type="doi">10.1590/1984-0462/2020/38/2018158</article-id>
<article-id pub-id-type="other">00610</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>TYROSINEMIA TYPE III: A CASE REPORT OF SIBLINGS AND LITERATURE
REVIEW</article-title>
<trans-title-group xml:lang="pt">
<trans-title>TIROSINEMIA TIPO III: DESCRIÇÃO DE CASO CLÍNICO EM IRMÃOS E REVISÃO
DA LITERATURA</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-2708-0165</contrib-id>
<name>
<surname>Barroso</surname>
<given-names>Fábio</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="corresp" rid="c1">*</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-0245-6840</contrib-id>
<name>
<surname>Correia</surname>
<given-names>Joana</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-1203-8180</contrib-id>
<name>
<surname>Bandeira</surname>
<given-names>Anabela</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-7401-4016</contrib-id>
<name>
<surname>Carmona</surname>
<given-names>Carla</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-6186-779X</contrib-id>
<name>
<surname>Vilarinho</surname>
<given-names>Laura</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-1683-1314</contrib-id>
<name>
<surname>Almeida</surname>
<given-names>Manuela</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-4977-8345</contrib-id>
<name>
<surname>Rocha</surname>
<given-names>Júlio César</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-9247-9391</contrib-id>
<name>
<surname>Martins</surname>
<given-names>Esmeralda</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<label>a</label>Centro Hospitalar Universitário do Porto, Porto, Portugal.</aff>
<aff id="aff2">
<label>b</label>National Institute of Health, Porto, Portugal.</aff>
<author-notes>
<corresp id="c1"><label>*</label>Corresponding author. E-mail:
<email>fabiodmb87@gmail.com</email> (F. Barroso).</corresp>
<fn fn-type="COI-statement" id="fn2">
<p>The authors declare no conflict of interests.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>6</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>38</volume>
<elocation-id>e2018158</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>12</month>
<year>2018</year>
</date>
<date date-type="online">
<day>21</day>
<month>5</month>
<year>2020</year>
</date>
</history>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution License</license-p>
</license>
</permissions>
<abstract>
<title>ABSTRACT</title>
<sec>
<title>Objective:</title>
<p> Tyrosinemia type III (HT III) is the rarest form of tyrosinemia, and the
full clinical spectrum of this disorder is still unknown. The neurological
involvement varies, including intellectual impairment and attention deficit
disorder with hyperactivity (ADHD). We report the case of two siblings
diagnosed with HT III at different ages.</p>
</sec>
<sec>
<title>Case description:</title>
<p> The index case was diagnosed by newborn screening for endocrine and
metabolic disorders, starting a low-protein diet immediately, with a
consistent decrease in tyrosine levels. By the age of three, the child
displayed a hyperactive behavior, starting treatment for ADHD two years
later. At seven years of age, he shows a slight improvement in terms of
behavior and attention span and has a cognitive performance slightly lower
than his peers, despite maintaining acceptable tyrosine levels. His sister,
who had a history of ADHD since age five, was diagnosed with HT III after
family screening at the age of eight. Despite initiating a dietetic
treatment, her behavior did not improve, and she has a mild intellectual
impairment.</p>
</sec>
<sec>
<title>Comments:</title>
<p> This is the first case report describing siblings with HT III who underwent
nutritional treatment with a low-protein diet in different phases of life,
with a better neurological and behavioral evaluation in the patient who
started treatment earlier.</p>
</sec>
</abstract>
<trans-abstract xml:lang="pt">
<title>RESUMO</title>
<sec>
<title>Objetivo:</title>
<p> A tirosinemia tipo III (TT III) é a forma mais rara das tirosinemias e o
espectro clínico desta entidade não está totalmente esclarecido. O
envolvimento neurológico é variável, incluindo o atraso cognitivo ou
transtorno do déficit de atenção com hiperatividade (TDAH). Descrevemos o
caso de dois irmãos que foram diagnosticados com TT III em idades
diferentes.</p>
</sec>
<sec>
<title>Descrição dos casos:</title>
<p> O caso índice foi diagnosticado no contexto do rastreio endócrino-metabólico
neonatal, tendo iniciado imediatamente dieta hipoproteica, com redução
consistente dos níveis de tirosina. Por volta dos três anos, foi detectado
um comportamento hiperativo, tendo iniciado dois anos depois tratamento para
o TDAH. Aos sete anos, apresenta leve melhora de comportamento e da atenção
e avaliação cognitiva levemente inferior ou pouco abaixo quando comparado a
crianças da mesma faixa etária, apesar de manter níveis aceitáveis de
tirosina. A sua irmã, com história de TDAH desde os cinco anos, foi
diagnosticada de TT III aos oito anos no contexto do rastreio de familiares.
Apesar de iniciar tratamento dietético, nenhum efeito foi notado em termos
de comportamento e a doente apresenta leve atraso cognitivo.</p>
</sec>
<sec>
<title>Comentários:</title>
<p> Este é o primeiro caso clínico descrito de irmãos com TT III que iniciaram
terapêutica dietética com dieta hipoproteica em diferentes fases da vida,
com melhor avaliação em termos neurológicos e comportamentais no doente que
iniciou tratamento mais precocemente.</p>
</sec>
</trans-abstract>
<kwd-group>
<title>Keywords:</title>
<kwd>Tyrosine</kwd>
<kwd>Tyrosinemias</kwd>
<kwd>Attention deficit disorder with hyperactivity</kwd>
<kwd>Metabolism</kwd>
</kwd-group>
<kwd-group xml:lang="pt">
<title>Palavras-chave:</title>
<kwd>Tirosina</kwd>
<kwd>Tirosinemias</kwd>
<kwd>Transtorno do déficit de atenção com hiperatividade</kwd>
<kwd>Metabolismo</kwd>
</kwd-group>
<counts>
<fig-count count="4"></fig-count>
<table-count count="4"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="21"></ref-count>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>INTRODUCTION</title>
<p>Tyrosine is a non-essential amino acid, obtained directly from diet or the
hydroxylation of phenylalanine. It is a precursor in the synthesis of
catecholamines, thyroxine, and melanin.<xref ref-type="bibr" rid="B1">
<sup>1</sup>
</xref>
</p>
<p>Tyrosinemia type III (OMIM 276710) is a rare inborn error of tyrosine metabolism
caused by mutations in the gene encoding the enzyme 4-hydroxyphenylpyruvate
dioxygenase (HPPD), which catalyzes the conversion of 4-hydroxyphenylpyruvate to
homogentisate, the second step in the tyrosine catabolic pathway. It is the rarest
form of tyrosinemia, being transmitted in an autosomal recessive form. This
metabolic disorder is characterized by elevated levels of serum tyrosine and
increased excretion of phenolic metabolites [4-hydroxyphenylpyruvate (4-HPP),
4-hydroxyphenyllactate (4-HPL) and hydrophenylacetate] in the urine. Only a few case
reports have been described in the literature, with a wide clinical phenotype
spectrum: some patients presented neurodevelopmental symptoms while others were
diagnosed by newborn screening, being asymptomatic.<xref ref-type="bibr" rid="B1">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B2">
<sup>2</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B3">
<sup>3</sup>
</xref>
</p>
<p>We report the case of two siblings with tyrosinemia type III who were diagnosed and
started treatment at different ages, presenting their clinical outcomes. A brief
literature review is also presented.</p>
<sec>
<title>CASE DESCRIPTION</title>
<sec>
<title>
Case 1
</title>
<p>The male patient is the third child from a Portuguese consanguineous couple
(third cousins), with an unremarkable family history. He was born at term by
vaginal delivery following an uneventful pregnancy, with an Apgar score of 9
and 10 at 1 and 5 minutes, respectively. His birth weight was 3,510 g
(89<sup>th</sup> percentile), length 50 cm (76<sup>th</sup> percentile),
and head circumference 35.5 cm (93<sup>rd</sup> percentile).</p>
<p>The newborn screening performed at the fifth day of life revealed elevated
tyrosine levels (526 µmol/L; cut-off values: &lt;248 µmol/L). A control
sample taken at the 29<sup>th</sup> day showed the persistence of elevated
plasma tyrosine levels (680 µmol/L), with high urinary excretion of 4-HPL
and 4-HPP and presence of N-acetyl-tyrosine and vanillactic acid.</p>
<p>The child started a protein-restricted diet supplemented with a tyrosine- and
phenylalanine-free amino acid mixture at 1-month-old. Subsequent metabolic
controls showed a consistent decrease in tyrosine levels: 280 µmol/L at 1.5
months, 262 µmol/L at 7 months, and 165 µmol/L at 12 months.</p>
<p>The diagnosis of tyrosinemia type III was confirmed by a genetic analysis
performed by amplifying exons one to 14 of the HPD gene using polymerase
chain reaction followed by DNA sequencing, which demonstrated a homozygous
mutation p.A33T (c.97G&gt;A).</p>
<p>His physical examination was normal, particularly with no ocular or skin
involvement, and presenting typical growth (weight curve at the
85‒97<sup>th</sup> percentile until 30 months and then at the
50‒85<sup>th</sup> percentile; height curve at the 50<sup>th</sup>
percentile until 30 months and then at the 50‒85<sup>th</sup> percentile;
normal head circumference). His neurological examination was normal, and he
had a brain magnetic resonance imaging at the age of 30 months showing no
abnormalities. His blood test analysis (full blood count, liver and renal
function, and electrolytes) was unremarkable.</p>
<p>His early psychomotor development was normal, with head control at less than
two months, sitting alone without support at approximately eight months, and
walking alone at 12 months. First words were spoken at 12 months, and he
constructed simple sentences at the age of 18 months. However, after the age
of three, language development progressed slowly, with sound articulation
problems.</p>
<p>The parents also reported a hyperactive behavior, with impulsivity and
inability to follow orders by the age of three. Throughout his pre-school
years, he was repeatedly considered incapable of following the level of
learning of his classmates.</p>
<p>A formal developmental assessment using the Griffiths Mental Development
Scale at 32 months showed a global developmental quotient (GDQ) of 88.9, and
the test was repeated at 54 months showing a GDQ of 87 (slightly lower score
compared to the children in his age group, with more evident difficulties on
the sub-scale of hearing and language).</p>
<p>At the age of five, the neurodevelopmental unit diagnosed him with Attention
Deficit Disorder with Hyperactivity (ADHD) with a combined subtype (DSM-V
criteria), and he initiated treatment with methylphenidate. He also started
speech therapy sessions.</p>
<p>Currently, at the age of seven, he shows a slight improvement in terms of
behavior and attention span and still undergoes speech therapy. He attends
elementary school (2<sup>nd</sup> grade) with no learning difficulties, and
at his last formal developmental assessment (Wechsler Intelligence Scale for
Children<sup>®</sup>, third edition, Portuguese version), he had an
intelligence quotient (IQ) of 78, a verbal IQ of 81, and a performance IQ of
82 (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p>
<p>
<fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>WISC-III subtest profile of patient 1.</title></caption><graphic xlink:href="1984-0462-rpp-38-e2018158-gf1"></graphic></fig>
</p>
<p>His tyrosine levels have been consistently below 300 µmol/L. On his last
nutritional status evaluation performed at the age of seven, he presented a
daily natural protein intake of 1 g/kg, supplemented with 1.1 g of amino
acids/kg from phenylalanine- and tyrosine-free amino acid mixtures. Body
composition analysis was considered adequate.</p>
</sec>
<sec>
<title>
Case 2
</title>
<p>A 15-year-old female, the eldest sibling of patient 1, was diagnosed with
tyrosinemia type III at eight years of age, after a family screening
following her brother’s diagnosis.</p>
<p>She was born at term by cesarean section (pelvic presentation) following an
uneventful pregnancy, with an Apgar score of 8 and 9 at 1 and 5 minutes,
respectively. Her birth weight was 4,030 g (87<sup>th</sup> percentile),
length 53 cm (87<sup>th</sup> percentile), and head circumference 36 cm
(83<sup>rd</sup> percentile). Her neonatal period was unremarkable, as
was her early psychomotor development. She had a history of primary
nocturnal enuresis and vesical instability, treated with desmopressin and
oxybutynin hydrochloride since the age of six.</p>
<p>She was diagnosed with ADHD at the age of five and treated with
methylphenidate and risperidone. She presented learning difficulties when
she attended elementary school (2<sup>nd</sup> grade), and was included in a
special education program at the age of ten.</p>
<p>At the time of diagnosis, her initial tyrosine level was 1,769 µmol/L. On the
first nutritional status evaluation, her daily natural protein intake was
1.4 g/kg. This value dropped to 1.08 g/kg, and she started taking
supplementation with 0.7 g of amino acids/kg from phenylalanine- and
tyrosine-free amino acid mixtures, enabling a consistent decrease of
tyrosine levels below 300 µmol/L.</p>
<p>Her physical examination and growth were normal (weight and height at the
50‒85<sup>th</sup> percentile), with an unremarkable neurological
examination. The genetic study revealed the same mutation as her brother in
homozygosity.</p>
<p>After initiating a low-protein diet, her behavior and school performance did
not improve. The minimum level of daily natural protein intake reached was
0.65 g/kg at 14 years of age. She is currently in 7<sup>th</sup> grade,
still in the special education program, and under treatment with
methylphenidate. Her latest formal developmental assessment (Wechsler
Intelligence Scale for Children<sup>®</sup>, third edition, Portuguese
version) revealed a global IQ score of 68, with a verbal IQ of 68 and a
performance IQ of 77 (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p>
<p>
<fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>WISC-III subtest profile of patient 2.</title></caption><graphic xlink:href="1984-0462-rpp-38-e2018158-gf2"></graphic></fig>
</p>
<p>She slowly began diet liberalization and is now with a daily natural protein
intake of 0.9 g/kg, combined with 0.8 g of amino acids/kg, maintaining
tyrosine levels below 300 µmol/L nevertheless.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>DISCUSSION</title>
<p>The symptoms of tyrosinemia type III are not well characterized, and there is no
apparent correlation between tyrosine serum levels, the clinical phenotype, and the
mutation type. As in the two cases presented, many patients have neurodevelopmental
manifestations, including intellectual impairment, learning difficulties, dyslexia,
attention deficit, hyperactivity, behavioral disturbance, ataxia, microcephaly,
hypotonia, and seizures, but a classical phenotype has not been described.<xref ref-type="bibr" rid="B1">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B2">
<sup>2</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B3">
<sup>3</sup>
</xref>
</p>
<p>Contrary to tyrosinemia types I and II, patients do not demonstrate any evidence of
hepato-renal dysfunction or skin or eye lesions. In 2015, an 11-year-old girl with
normal development and no neurological signs was diagnosed with tyrosinemia type III
following the investigation of recurrent proteinuria (9-17 mg/L); in this case,
laboratory tests revealed elevated serum tyrosine levels, which led to the diagnosis
of the disease. However, it was not clear if the nephrological complications were
associated with tyrosinemia type III.<xref ref-type="bibr" rid="B4">
<sup>4</sup>
</xref>
</p>
<p>In a 2001 review, which included 13 patients, the most common long-term complication
was intellectual impairment (75% patients). Five patients were diagnosed by newborn
screening, three of whom started a low-tyrosine and -phenylalanine diet after
diagnosis; among them, two had no symptoms and presented normal development at 13
months and five years and five months, respectively, while the third had a delayed
psychomotor development but demonstrated an average developmental quotient at the
age of four (Griffiths Mental Development Scale). One patient only started treatment
at 8 months of age, when developmental retardation was detected, and another who was
not treated showed intellectual impairment. Eight patients were diagnosed after the
neonatal period, seven of them because of neurologic signs and one due to
developmental delay. Only one patient had normal development at 17 years of
age.<xref ref-type="bibr" rid="B2">
<sup>2</sup>
</xref>
</p>
<p>The etiology of the neurological manifestations is not known but could be related to
hypertyrosinemia as in tyrosinemia types I and II. Tyrosine and/or its derivatives
seemed to be neurotoxic metabolites, and mental delay was associated with increased
plasma concentrations of these substances. Several studies revealed that
hypertyrosinemia inhibits the functioning of respiratory chain complexes,
compromises the Krebs cycle, and decreases creatine kinase and pyruvate kinase
activities, inducing an oxidative stress status and an impairment of energy
metabolism in the cerebral cortex of rats.<xref ref-type="bibr" rid="B5">
<sup>5</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B6">
<sup>6</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B7">
<sup>7</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B8">
<sup>8</sup>
</xref>
</p>
<p>Patients detected by newborn screening appear to have fewer neurological symptoms and
a lower degree of cognitive impairment compared to those diagnosed later in
life.<xref ref-type="bibr" rid="B2">
<sup>2</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B3">
<sup>3</sup>
</xref> However, it is unclear if the clinical outcome is determined by the decrease
in plasma tyrosine levels, and the neurological evolution can vary despite similar
tyrosine levels.<xref ref-type="bibr" rid="B2">
<sup>2</sup>
</xref> Besides, there are asymptomatic patients diagnosed later in childhood or
adolescence who never developed neurological or behavioral symptoms.<xref ref-type="bibr" rid="B4">
<sup>4</sup>
</xref>
</p>
<p>Another proposed hypothesis is that neurological impairment could be explained by an
excessive nitric oxide release, which could contribute to neuronal damage.<xref ref-type="bibr" rid="B9">
<sup>9</sup>
</xref>
</p>
<p>Although it is unclear if lowering tyrosine levels can alter the natural history of
the disease, treating it with a low-protein diet, at least in early childhood, to
maintain tyrosine levels between 200 and 500 µmol/L has been considered
reasonable.<xref ref-type="bibr" rid="B10">
<sup>10</sup>
</xref>
</p>
<p>Both our patients started nutritional treatment after diagnosis, maintaining
tyrosinemia levels below 300 µmol/L afterward. However, while one was detected by
newborn screening, the other was eight years old at the time of diagnosis and
already symptomatic with learning difficulties. Clinically, they both presented ADHD
requiring pharmacological treatment, but patient 1 had a better cognitive outcome
despite being below average compared to the healthy population group. He attends the
2<sup>nd</sup> grade with a normal curriculum.</p>
<p>In patient 2, despite initiating treatment, her behavior did not improve, and she has
a mild intellectual impairment. A decision to gradually increase natural protein
intake was made, and she has maintained acceptable tyrosine levels, although she
still takes phenylalanine- and tyrosine-free amino acid supplements to satisfy her
nitrogen needs. These findings have been reported, and many patients seem to be able
to maintain these levels after childhood, without diet control.<xref ref-type="bibr" rid="B2">
<sup>2</sup>
</xref>
</p>
<p>Currently, a significant number of metabolic disorders related to major psychiatric
diseases remain underdiagnosed for years before more specific organic signs become
evident. Metabolic diseases most associated with ADHD are succinic semialdehyde
dehydrogenase deficiency, phenylketonuria, X-linked ichthyosis, and
mucopolysaccharidosis type III (Sanfilippo syndrome).<xref ref-type="bibr" rid="B11">
<sup>11</sup>
</xref>
</p>
<p>Establishing a genotype-phenotype correlation in tyrosinemia is difficult since the
literature has very few cases described on the subject, and only some of them
identify distinct mutations. <xref ref-type="table" rid="t1">Tables 1</xref> and
<xref ref-type="table" rid="t2">2</xref> summarize the main clinical and
analytical characteristics of patients known to date.</p>
<p>
<table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Summary of patients with tyrosinemia type III detected by neonatal
screening.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Case-study </th><th align="center" colspan="1" rowspan="1">Gender</th><th align="center" colspan="1" rowspan="1">Age at diagnosis</th><th align="center" colspan="1" rowspan="1">Family history </th><th align="center" colspan="1" rowspan="1">Form of presentation</th><th align="center" colspan="1" rowspan="1">Neurological abnormalities</th><th align="center" colspan="1" rowspan="1">Brain image</th><th align="center" colspan="1" rowspan="1">Plasma tyrosinemia at diagnosis</th><th align="center" colspan="1" rowspan="1">Genetic study</th><th align="center" colspan="1" rowspan="1">Treatment</th><th align="center" colspan="1" rowspan="1">Follow-up</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Patient 1</td><td align="center" colspan="1" rowspan="1">Male</td><td align="center" colspan="1" rowspan="1">Neonatal screening</td><td align="center" colspan="1" rowspan="1">Consanguineous parents </td><td align="center" colspan="1" rowspan="1">Asymptomatic</td><td align="center" colspan="1" rowspan="1">Speech delay, ADHD</td><td align="center" colspan="1" rowspan="1">Normal</td><td align="center" colspan="1" rowspan="1">526 µmol/L</td><td align="center" colspan="1" rowspan="1">Homozygous for A33T mutation in the HPD gene</td><td align="center" colspan="1" rowspan="1">Low-Phe/Tyr diet</td><td align="center" colspan="1" rowspan="1">“Borderline” development (7 y)</td></tr><tr><td align="left" colspan="1" rowspan="1">1- Preece et al.<xref ref-type="bibr" rid="B12">
<sup>12</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Female</td><td align="center" colspan="1" rowspan="1">Neonatal screening</td><td align="center" colspan="1" rowspan="1">Crouzon syndrome</td><td align="center" colspan="1" rowspan="1">Asymptomatic </td><td align="center" colspan="1" rowspan="1">Developmental delay at 8 mo </td><td align="center" colspan="1" rowspan="1">Not described/performed </td><td align="center" colspan="1" rowspan="1">355 µmol/L</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">Low-Phe/Tyr diet</td><td align="center" colspan="1" rowspan="1">Learning difficulties (7 y) Crouzon syndrome
</td></tr><tr><td align="left" colspan="1" rowspan="1">2- Standing et al.<xref ref-type="bibr" rid="B13">
<sup>13</sup>
</xref> and Rüetschi et al.<xref ref-type="bibr" rid="B14">
<sup>14</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Female</td><td align="center" colspan="1" rowspan="1">Neonatal screening</td><td align="center" colspan="1" rowspan="1">First cousin of patient 3 (Table 1)
Consanguineous parents </td><td align="center" colspan="1" rowspan="1">Asymptomatic</td><td align="center" colspan="1" rowspan="1">Mild jitteriness, brisk tendon reflexes </td><td align="center" colspan="1" rowspan="1">Abnormal appearance in subcortical and brainstem
white matter (30 mo)</td><td align="center" colspan="1" rowspan="1">1094 µmol/L</td><td align="center" colspan="1" rowspan="1">Homozygous for Y258X mutation in the HPD
gene</td><td align="center" colspan="1" rowspan="1">Low-Phe/Tyr diet</td><td align="center" colspan="1" rowspan="1">Delayed psychomotor development (5 y)</td></tr><tr><td align="left" colspan="1" rowspan="1">3- Standing et al.<xref ref-type="bibr" rid="B13">
<sup>13</sup>
</xref> and Rüetschi et al.<xref ref-type="bibr" rid="B14">
<sup>14</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Male</td><td align="center" colspan="1" rowspan="1">Neonatal screening</td><td align="center" colspan="1" rowspan="1">First cousin of patient 2 (Table 1)
Consanguineous parents </td><td align="center" colspan="1" rowspan="1">Neonatal hepatitis</td><td align="center" colspan="1" rowspan="1">None </td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">Range: 500-1000 µmol/L in the first 19 mo</td><td align="center" colspan="1" rowspan="1">Homozygous for Y258X mutation in the HPD
gene</td><td align="center" colspan="1" rowspan="1">Normal diet</td><td align="center" colspan="1" rowspan="1">Mild intellectual impairment (17 y)</td></tr><tr><td align="left" colspan="1" rowspan="1">4- Ellaway et al.<xref ref-type="bibr" rid="B15">
<sup>15</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Not described</td><td align="center" colspan="1" rowspan="1">Neonatal screening</td><td align="center" colspan="1" rowspan="1">Not relevant </td><td align="center" colspan="1" rowspan="1">Asymptomatic</td><td align="center" colspan="1" rowspan="1">None</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">937 µmol/L</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">Low-Phe/Tyr diet</td><td align="center" colspan="1" rowspan="1">Normal development (13 mo)</td></tr><tr><td align="left" colspan="1" rowspan="1">5- Ellaway et al.<xref ref-type="bibr" rid="B15">
<sup>15</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Female</td><td align="center" colspan="1" rowspan="1">Neonatal screening</td><td align="center" colspan="1" rowspan="1">Not relevant</td><td align="center" colspan="1" rowspan="1">Asymptomatic</td><td align="center" colspan="1" rowspan="1">None</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">581 µmol/L</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">Low-Phe/Tyr diet</td><td align="center" colspan="1" rowspan="1">Normal development (5 y 5 mo)</td></tr><tr><td align="left" colspan="1" rowspan="1">6- Heylen et al.<xref ref-type="bibr" rid="B10">
<sup>10</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Male</td><td align="center" colspan="1" rowspan="1">Neonatal screening</td><td align="center" colspan="1" rowspan="1">Consanguineous parents </td><td align="center" colspan="1" rowspan="1">Asymptomatic</td><td align="center" colspan="1" rowspan="1">None</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">398 µmol/L</td><td align="center" colspan="1" rowspan="1">Homozygous splice donor mutation in intron 11,
IVS11+1G&gt;A in the HPD gene</td><td align="center" colspan="1" rowspan="1">Low-Phe/Tyr diet</td><td align="center" colspan="1" rowspan="1">Normal development (30 mo)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>ADHD: attention deficit disorder with hyperactivity; HPD:
hydroxyphenylpyruvate dioxygenase; mo: months; Phe: phenylalanine;
Tyr: tyrosine; y: years.</p></fn></table-wrap-foot></table-wrap>
</p>
<p>
<table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Summary of patients with tyrosinemia type III detected after the
neonatal period.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Case-study </th><th align="center" colspan="1" rowspan="1">Gender</th><th align="center" colspan="1" rowspan="1">Age at diagnosis</th><th align="center" colspan="1" rowspan="1">Family history </th><th align="center" colspan="1" rowspan="1">Form of presentation</th><th align="center" colspan="1" rowspan="1">Neurological abnormalities</th><th align="center" colspan="1" rowspan="1">Brain image</th><th align="center" colspan="1" rowspan="1">Plasma tyrosinemia at diagnosis</th><th align="center" colspan="1" rowspan="1">Genetic study</th><th align="center" colspan="1" rowspan="1">Treatment</th><th align="center" colspan="1" rowspan="1">Follow-up</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Patient 2</td><td align="center" colspan="1" rowspan="1">Female</td><td align="center" colspan="1" rowspan="1">8 y</td><td align="center" colspan="1" rowspan="1">Consanguineous parents </td><td align="center" colspan="1" rowspan="1">Learning difficulties</td><td align="center" colspan="1" rowspan="1">Psychomotor retardation, ADHD</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">1769 µmol/L</td><td align="center" colspan="1" rowspan="1">Homozygous for A33T mutation in the HPD gene</td><td align="center" colspan="1" rowspan="1">Low-Phe/Tyr diet </td><td align="center" colspan="1" rowspan="1">Mild intellectual impairment (15 y)</td></tr><tr><td align="left" colspan="1" rowspan="1">1- Endo et al.<xref ref-type="bibr" rid="B16">
<sup>16</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Male</td><td align="center" colspan="1" rowspan="1">Infancy</td><td align="center" colspan="1" rowspan="1">Parents were siblings mother had
hypertyrosinemia</td><td align="center" colspan="1" rowspan="1">Seizures and pneumonia at day 21 of life</td><td align="center" colspan="1" rowspan="1">Seizures, encephalopathy</td><td align="center" colspan="1" rowspan="1">Mild cerebral atrophy</td><td align="center" colspan="1" rowspan="1">640 µmol/L</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">Low-Phe/Tyr diet</td><td align="center" colspan="1" rowspan="1">Died due to accidental asphyxiation (day
105)</td></tr><tr><td align="left" colspan="1" rowspan="1">2- Giardini et al.<xref ref-type="bibr" rid="B17">
<sup>17</sup>
</xref> and D’Eufemia et al.<xref ref-type="bibr" rid="B18">
<sup>18</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B19">
<sup>19</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Female</td><td align="center" colspan="1" rowspan="1">17 mo</td><td align="center" colspan="1" rowspan="1">Not relevant</td><td align="center" colspan="1" rowspan="1">Acute ataxia, confusion, motor incoordination,
hypotonia, absent tendon reflexes</td><td align="center" colspan="1" rowspan="1">Recovered from all symptoms </td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">624 µmol/L</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">Low-protein diet until 3 y</td><td align="center" colspan="1" rowspan="1">Autoimmune thyroiditis (9 y) Normal development
(17 y)</td></tr><tr><td align="left" colspan="1" rowspan="1">3- Cerrone et al.<xref ref-type="bibr" rid="B3">
<sup>3</sup>
</xref> and Rüetschi et al.<xref ref-type="bibr" rid="B14">
<sup>14</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Male</td><td align="center" colspan="1" rowspan="1">3.5 y</td><td align="center" colspan="1" rowspan="1">Not relevant</td><td align="center" colspan="1" rowspan="1">Developmental delay from 8 mo</td><td align="center" colspan="1" rowspan="1">Psychomotor retardation, hyperactivity,
self-injurious behavior, severe speech delay</td><td align="center" colspan="1" rowspan="1">Normal</td><td align="center" colspan="1" rowspan="1">532 µmol/L</td><td align="center" colspan="1" rowspan="1">Heterozygous for Y200X and I335M mutations in the
HPD gene</td><td align="center" colspan="1" rowspan="1">Low-Phe/Tyr diet until 12 y</td><td align="center" colspan="1" rowspan="1">Severe intellectual impairment (14 y)</td></tr><tr><td align="left" colspan="1" rowspan="1">4- Tomoeda et al.<xref ref-type="bibr" rid="B20">
<sup>20</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Male</td><td align="center" colspan="1" rowspan="1">7 weeks</td><td align="center" colspan="1" rowspan="1">Not relevant</td><td align="center" colspan="1" rowspan="1">Neonatal restlessness, reduced head control </td><td align="center" colspan="1" rowspan="1">Microcephaly</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">594 µmol/L during treatment</td><td align="center" colspan="1" rowspan="1">Homozygous for A268V mutation in the HPD
gene</td><td align="center" colspan="1" rowspan="1">Low Phe/Tyr diet until 17 y, then low-protein
diet</td><td align="center" colspan="1" rowspan="1">Moderate intellectual impairment (19 y)</td></tr><tr><td align="left" colspan="1" rowspan="1">5- Rüetschi et al.<xref ref-type="bibr" rid="B14">
<sup>14</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Male</td><td align="center" colspan="1" rowspan="1">7.5 y</td><td align="center" colspan="1" rowspan="1">Brother of patient 4 (Table 2) Consanguineous
parents </td><td align="center" colspan="1" rowspan="1">Urolithiasis</td><td align="center" colspan="1" rowspan="1">Essential tremor</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">830 µmol/L</td><td align="center" colspan="1" rowspan="1">Homozygous for Y160C mutation in the HPD
gene</td><td align="center" colspan="1" rowspan="1">Normal diet</td><td align="center" colspan="1" rowspan="1">Mild intellectual impairment (7.5 y) Lost to
follow-up</td></tr><tr><td align="left" colspan="1" rowspan="1">6- Rüetschi et al.<xref ref-type="bibr" rid="B14">
<sup>14</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Male</td><td align="center" colspan="1" rowspan="1">18 y</td><td align="center" colspan="1" rowspan="1">Brother of patient 5 (Table 2) Consanguineous
parents </td><td align="center" colspan="1" rowspan="1">Psychomotor retardation</td><td align="center" colspan="1" rowspan="1">Essential tremor</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">262 µmol/L</td><td align="center" colspan="1" rowspan="1">Homozygous for Y160C mutation in the HPD
gene</td><td align="center" colspan="1" rowspan="1">Normal diet</td><td align="center" colspan="1" rowspan="1">Lost to follow-up</td></tr><tr><td align="left" colspan="1" rowspan="1">7- Ellaway et al.<xref ref-type="bibr" rid="B15">
<sup>15</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Male</td><td align="center" colspan="1" rowspan="1">14 y</td><td align="center" colspan="1" rowspan="1">Consanguineous parents </td><td align="center" colspan="1" rowspan="1">Mild psychomotor retardation, generalized
seizures</td><td align="center" colspan="1" rowspan="1">Suspected seizures since 2 y</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">913 µmol/L</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">Low-protein diet initially, then ceased</td><td align="center" colspan="1" rowspan="1">Intellectual impairment (18 y)</td></tr><tr><td align="left" colspan="1" rowspan="1">8- Ellaway et al.<xref ref-type="bibr" rid="B15">
<sup>15</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Not described</td><td align="center" colspan="1" rowspan="1">18 mo</td><td align="center" colspan="1" rowspan="1">Not relevant</td><td align="center" colspan="1" rowspan="1">Developmental delay</td><td align="center" colspan="1" rowspan="1">None</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">1305 µmol/L</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">Low-Phe/Tyr diet</td><td align="center" colspan="1" rowspan="1">Mild global developmental delay (6 y)</td></tr><tr><td align="left" colspan="1" rowspan="1">9- Tahiroglu et al.<xref ref-type="bibr" rid="B21">
<sup>21</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Male</td><td align="center" colspan="1" rowspan="1">2 y </td><td align="center" colspan="1" rowspan="1">Not described </td><td align="center" colspan="1" rowspan="1">Developmental delay from 15 mo</td><td align="center" colspan="1" rowspan="1">Psychomotor retardation, hyperactivity, autistic
symptoms</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">“Elevated levels”</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">Low-Tyr diet</td><td align="center" colspan="1" rowspan="1">Severe intellectual impairment (9 y) Persistence
of hyperactivity</td></tr><tr><td align="left" colspan="1" rowspan="1">10- Szymanska et al.<xref ref-type="bibr" rid="B4">
<sup>4</sup>
</xref>
</td><td align="center" colspan="1" rowspan="1">Female</td><td align="center" colspan="1" rowspan="1">11 y </td><td align="center" colspan="1" rowspan="1">Not described</td><td align="center" colspan="1" rowspan="1">Recurrent proteinuria since 7 y</td><td align="center" colspan="1" rowspan="1">None</td><td align="center" colspan="1" rowspan="1">Not described/performed</td><td align="center" colspan="1" rowspan="1">439 µmol/L</td><td align="center" colspan="1" rowspan="1">Homozygous for T160C mutation in the HPD
gene</td><td align="center" colspan="1" rowspan="1">Normal diet</td><td align="center" colspan="1" rowspan="1">Normal development (11 y)</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>ADHD: attention deficit disorder with hyperactivity; HPD:
hydroxyphenylpyruvate dioxygenase; mo: months; Phe: phenylalanine;
Tyr: tyrosine; y: years.</p></fn></table-wrap-foot></table-wrap>
</p>
<p>To our knowledge, this is the first case report of siblings with tyrosinemia type III
who underwent nutritional treatment with a low-protein diet in different life
stages, with the one who started it earlier and during an asymptomatic phase showing
better results in terms of neurological and behavioral outcomes.</p>
<p>Both patients presented ADHD as a neurological manifestation. Therefore, we emphasize
the importance of conducting a metabolic study in children with this disorder who do
not respond adequately to pharmacological treatment.</p>
<p>Although the pathophysiology of neuronal injury in tyrosinemia type III is not
completely explained by the accumulation of tyrosine in the central nervous system,
a restrictive tyrosine and phenylalanine diet is recommended during childhood.
Further studies and collection of information on these patients are necessary to
understand the consequences of HPPD deficiency, the mechanisms of brain injury, and
the long-term outcome in patients with this rare form of tyrosinemia.</p>
</sec>
</body>
<back>
<ack>
<title>ACKNOWLEDGMENTS</title>
<p>We thank the parents of the patients for their kind cooperation. Furthermore, we
thank the contribution of the medical-laboratory assistants of our institutes.</p>
</ack>
<fn-group>
<title>Funding</title>
<fn fn-type="supported-by" id="fn1">
<p>This study did not receive funding.</p>
</fn>
</fn-group>
<ref-list>
<title>REFERENCES</title>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russo</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Tanguay</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>Tyrosinemia: a review</article-title>
<source/>Pediatr Dev Pathol
          <year>2001</year>
<volume>4</volume>
<fpage>212</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1007/s100240010146</pub-id>
<pub-id pub-id-type="pmid">11370259</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ellaway</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Holme</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Standing</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Preece</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ploechl</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Outcome of tyrosinemia type III</article-title>
<source/>J Inherit Metab Dis
          <year>2001</year>
<volume>24</volume>
<fpage>824</fpage>
<lpage>832</lpage>
<pub-id pub-id-type="doi">10.1023/a:1013936107064</pub-id>
<pub-id pub-id-type="pmid">11916315</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cerone</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Holme</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schiaffino</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Caruso</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Maritano</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Tyrosinemia type III: diagnosis and ten-year
follow-up</article-title>
<source/>Acta Paediatr
          <year>1997</year>
<volume>86</volume>
<fpage>1013</fpage>
<lpage>1015</lpage>
<pub-id pub-id-type="doi">10.1111/j.1651-2227.1997.tb15192.x</pub-id>
<pub-id pub-id-type="pmid">9343288</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szymanska</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sredzinska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ciara</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Piekutowska-Abramczuk</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ploski</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rokicki</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tyrosinemia type III in an asymptomatic girl</article-title>
<source/>Mol Genet Metab Rep
          <year>2015</year>
<volume>5</volume>
<fpage>48</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgmr.2015.10.004</pub-id>
<pub-id pub-id-type="pmid">28649543</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andrade</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Gemelli</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rojas</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Funchal</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dutra-Filho</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Wannmacher</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Tyrosine inhibits creatine kinase activity in cerebral cortex of
young rats</article-title>
<source/>Metab Brain Dis
          <year>2011</year>
<volume>26</volume>
<fpage>221</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1007/s11011-011-9255-9</pub-id>
<pub-id pub-id-type="pmid">21789565</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macedo</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Carvalho-Silva</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Olegario</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Goncalves</surname>
<given-names>RC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of acute administration of L-tyrosine on oxidative stress
parameters in brain of young rats</article-title>
<source/>Neurochem Res
          <year>2013</year>
<volume>38</volume>
<fpage>2625</fpage>
<lpage>2630</lpage>
<pub-id pub-id-type="doi">10.1007/s11064-013-1180-3</pub-id>
<pub-id pub-id-type="pmid">24135880</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Prá</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Carvalho-Silva</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Scaini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Leffa</surname>
<given-names>DD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>L-tyrosine induces DNA damage in brain and blood of
rats</article-title>
<source/>Neurochem Res
          <year>2014</year>
<volume>39</volume>
<fpage>202</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.1007/s11064-013-1207-9</pub-id>
<pub-id pub-id-type="pmid">24297753</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teodorak</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Scaini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Carvalho-Silva</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Teixeira</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Rebelo</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antioxidants reverse the changes in energy metabolism of rat
brain after chronic administration of L.-tyrosine</article-title>
<source/>Metab Brain Dis
          <year>2017</year>
<volume>32</volume>
<fpage>557</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="doi">10.1007/s11011-016-9936-5</pub-id>
<pub-id pub-id-type="pmid">27924409</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Eufemia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Finocchiaro</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Celli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Raccio</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Properzi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zicari</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Increased nitric oxide release by neutrophils of a patient with
tyrosinemia type III</article-title>
<source/>Biomed Pharmacother
          <year>2009</year>
<volume>63</volume>
<fpage>359</fpage>
<lpage>361</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopha.2008.06.030</pub-id>
<pub-id pub-id-type="pmid">18657947</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heylen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Scherer</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Marie</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nassogne</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Tyrosinemia Type III detected via neonatal screening: management
and outcome</article-title>
<source/>Mol Genet Metab
          <year>2012</year>
<volume>107</volume>
<fpage>605</fpage>
<lpage>607</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2012.09.002</pub-id>
<pub-id pub-id-type="pmid">23036342</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simons</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Eyskens</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Glazemakers</surname>
<given-names>I</given-names>
</name>
<name>
<surname>West</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Can psychiatric childhood disorders be due to inborn errors of
metabolism?</article-title>
<source/>Eur Child Adolesc Psychiatry
          <year>2017</year>
<volume>26</volume>
<fpage>143</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1007/s00787-016-0908-4</pub-id>
<pub-id pub-id-type="pmid">27695954</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Preece</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Rylance</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>RGF</given-names>
</name>
</person-group>
<article-title>A new case of tyrosinemia type III detected by neonatal
screening</article-title>
<source/>J Inherit Metab Dis
          <year>1996</year>
<volume>19</volume>
<issue>1</issue>
<fpage>32</fpage>
<lpage>32</lpage>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Standing</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Dunger</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rüetschi</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Holme</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Tyrosinemia type III detected by neonatal
screening</article-title>
<source/>J Inherit Metab Dis
          <year>1998</year>
<volume>21</volume>
<issue>2</issue>
<fpage>25</fpage>
<lpage>25</lpage>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rüetschi</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Cerone</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pérez-Cerda</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schiaffino</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Standing</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ugarte</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene (HPD)
in patients with tyrosinemia type III</article-title>
<source/>Hum Genet
          <year>2000</year>
<volume>106</volume>
<fpage>654</fpage>
<lpage>662</lpage>
<pub-id pub-id-type="doi">10.1007/s004390000307</pub-id>
<pub-id pub-id-type="pmid">10942115</pub-id>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ellaway</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Holme</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Standing</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Preece</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ploechl</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Outcome of tyrosinemia type III</article-title>
<source/>J Inherit Metab Dis
          <year>2001</year>
<volume>24</volume>
<fpage>824</fpage>
<lpage>832</lpage>
<pub-id pub-id-type="doi">10.1023/A:1013936107064</pub-id>
<pub-id pub-id-type="pmid">11916315</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Endo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kitano</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Uehara</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Nagata</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Matsuda</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Shinka</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Four-Hydroxyphenylpyruvic acid oxidase de¢ciency with normal
fumarylacetoacetase: a new variant of hereditary
hypertyrosinaemia</article-title>
<source/>Pediatr Res
          <year>1983</year>
<volume>17</volume>
<fpage>92</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1203/00006450-198302000-00002</pub-id>
<pub-id pub-id-type="pmid">6828337</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giardini</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Cantani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kennaway</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>D’Eufemia</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Chronic tyrosinemia associated with 4-hydroxyphenylpyruvate
dioxygenase deficiency with acute intermittent ataxia and without visceral
and bone involvement</article-title>
<source/>Pediatr Res
          <year>1983</year>
<volume>17</volume>
<fpage>25</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1203/00006450-198301000-00005</pub-id>
<pub-id pub-id-type="pmid">6132360</pub-id>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Eufemia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Giardini</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Cantani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Martino</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Finocchiaro</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Autoimmune thyroiditis in a case of tyrosinemia
III</article-title>
<source/>J Inherit Metab Dis
          <year>1992</year>
<volume>15</volume>
<fpage>861</fpage>
<lpage>862</lpage>
<pub-id pub-id-type="doi">10.1007/bf01800222</pub-id>
<pub-id pub-id-type="pmid">1293381</pub-id>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Eufemia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Finocchiaro</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Celli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Viozzi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Giardini</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Immunological abnormalities in a patient with tyrosinemia type
III</article-title>
<source/>J Inherit Metab Dis
          <year>1995</year>
<volume>18</volume>
<fpage>355</fpage>
<lpage>356</lpage>
<pub-id pub-id-type="doi">10.1007/bf00710429</pub-id>
<pub-id pub-id-type="pmid">7474904</pub-id>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomoeda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Awata</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Matsuura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matsuda</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ploechl</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Milovac</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the 4-Hydroxyphenylpyruvic acid dehydrogenase gene
are responsible for tyrosinemia type III and hawkinisinuria</article-title>
<source/>Mol Genet Metab
          <year>2000</year>
<volume>71</volume>
<fpage>506</fpage>
<lpage>510</lpage>
<pub-id pub-id-type="doi">10.1006/mgme.2000.3085</pub-id>
<pub-id pub-id-type="pmid">11073718</pub-id>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tahiroğlu</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Mungan</surname>
<given-names>NÖ</given-names>
</name>
<name>
<surname>Firat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Avci</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Autism symptoms related to tyrosinemia type III: A case
report</article-title>
<source/>Turk J Endocrinol Metab
          <year>2008</year>
<volume>12</volume>
<fpage>55</fpage>
<lpage>56</lpage>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>